Discover 3 Undiscovered Gems In Hong Kong With Strong Fundamentals

In This Article:

The Hong Kong market has shown resilience amid global economic fluctuations, with the Hang Seng Index gaining 0.85% recently despite broader concerns about deflationary pressures in China. As investors navigate this complex landscape, identifying stocks with strong fundamentals becomes crucial for achieving long-term growth. In this article, we will explore three undiscovered gems in Hong Kong that exhibit robust financial health and potential for sustained performance amidst current market conditions.

Top 10 Undiscovered Gems With Strong Fundamentals In Hong Kong

Name

Debt To Equity

Revenue Growth

Earnings Growth

Health Rating

E-Commodities Holdings

23.22%

6.87%

31.81%

★★★★★★

S.A.S. Dragon Holdings

37.35%

4.13%

12.06%

★★★★★★

COSCO SHIPPING International (Hong Kong)

NA

-12.97%

12.59%

★★★★★★

PW Medtech Group

NA

17.93%

-2.70%

★★★★★★

China Leon Inspection Holding

17.06%

24.06%

27.08%

★★★★★★

Tianyun International Holdings

10.09%

-5.59%

-9.92%

★★★★★★

JiaXing Gas Group

17.72%

26.04%

22.07%

★★★★★☆

Hung Hing Printing Group

3.97%

-2.51%

33.57%

★★★★★☆

Changjiu Holdings

14.09%

12.87%

-4.74%

★★★★★☆

Mulsanne Group Holding

186.88%

-12.02%

-43.54%

★★★★☆☆

Click here to see the full list of 175 stocks from our SEHK Undiscovered Gems With Strong Fundamentals screener.

Below we spotlight a couple of our favorites from our exclusive screener.

YiChang HEC ChangJiang Pharmaceutical

Simply Wall St Value Rating: ★★★★★☆

Overview: YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (SEHK:1558) is a pharmaceutical company engaged in the research, development, manufacturing, and sales of pharmaceutical products with a market cap of HK$8.61 billion.

Operations: YiChang HEC ChangJiang Pharmaceutical generates revenue primarily from the sales of pharmaceutical products, totaling CN¥6.29 billion. The company's net profit margin for the latest period is %.

YiChang HEC ChangJiang Pharmaceutical, a smaller player in the Hong Kong market, has seen its earnings grow by an astounding 2501.2% over the past year, significantly outpacing the industry average of 0.1%. Despite this impressive growth, its earnings have declined by 15.7% annually over the last five years. The company’s debt-to-equity ratio has risen from 1.5% to 30.5%, yet it remains satisfactory at a net debt to equity ratio of 9.2%. Recently, they announced a special dividend of HK$1.5 per share, adding value for shareholders amidst these mixed financial signals.